Quarterly report · Q1
4583.TEDINET S100QPID
Period2023-01-01 → 2023-03-31
Filed2023-05-11
StandardJapan GAAP
ConsolidatedNo
Data checks10 of 10 passed
Key figures · 32
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥169m | 2023-01-01 → 2023-03-31 | Standalone | Net sales |
| Revenue | ¥631m | 2022-01-01 → 2022-12-31 | Standalone | Net sales (5-year summary) |
| Revenue | ¥129m | 2022-01-01 → 2022-03-31 | Standalone | Net sales |
| Operating income | −¥226m | 2023-01-01 → 2023-03-31 | Standalone | Operating income |
| Operating income | −¥487m | 2022-01-01 → 2022-03-31 | Standalone | Operating income |
| Ordinary income | −¥227m | 2023-01-01 → 2023-03-31 | Standalone | Ordinary income |
| Ordinary income | −¥1.2bn | 2022-01-01 → 2022-12-31 | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥491m | 2022-01-01 → 2022-03-31 | Standalone | Ordinary income |
| Profit before tax | −¥226m | 2023-01-01 → 2023-03-31 | Standalone | Income before income taxes |
| Profit before tax | −¥491m | 2022-01-01 → 2022-03-31 | Standalone | Income before income taxes |
| Net income | −¥228m | 2023-01-01 → 2023-03-31 | Standalone | Profit loss |
| Net income | −¥1.2bn | 2022-01-01 → 2022-12-31 | Standalone | Net income loss (5-year summary) |
| Net income | −¥492m | 2022-01-01 → 2022-03-31 | Standalone | Profit loss |
| Total assets | ¥2.1bn | at 2023-03-31 | Standalone | Assets |
| Total assets | ¥2.2bn | at 2022-12-31 | Standalone | Assets |
| Total assets | ¥2.1bn | at 2022-03-31 | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥524m | at 2023-03-31 | Standalone | Liabilities |
| Total liabilities | ¥425m | at 2022-12-31 | Standalone | Liabilities |
| Net assets / equity | ¥1.6bn | at 2023-03-31 | Standalone | Net assets |
| Net assets / equity | ¥1.8bn | at 2022-12-31 | Standalone | Net assets |
| Net assets / equity | ¥1.7bn | at 2022-03-31 | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥1.6bn | at 2023-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥1.7bn | at 2022-12-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥-4.7 | 2023-01-01 → 2023-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-28.26 | 2022-01-01 → 2022-12-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-11.66 | 2022-01-01 → 2022-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| Equity ratio | 74.3% | at 2023-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 80.2% | at 2022-12-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 76.3% | at 2022-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Shares issued | 48,423,500 | at 2023-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 48,423,500 | at 2022-12-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 42,409,900 | at 2022-03-31 | Standalone | Total number of issued shares (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 16
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | segment profit | 2023-01-01 → 2023-03-31 | −¥128m |
| jpcrp040300-q1r_E26096-000Drug Discovery And Developmentreportable segment | segment profit | 2023-01-01 → 2023-03-31 | −¥194m |
| jpcrp040300-q1r_E26096-000Drug Discovery Supportreportable segment | revenue | 2023-01-01 → 2023-03-31 | ¥169m |
| jpcrp040300-q1r_E26096-000Drug Discovery Supportreportable segment | revenue external | 2023-01-01 → 2023-03-31 | ¥169m |
| jpcrp040300-q1r_E26096-000Drug Discovery Supportreportable segment | segment profit | 2023-01-01 → 2023-03-31 | ¥96m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-01-01 → 2023-03-31 | ¥169m |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-01-01 → 2023-03-31 | ¥169m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-01-01 → 2023-03-31 | −¥98m |
| Reconciling Itemsreconciling | segment profit | 2022-01-01 → 2022-03-31 | −¥111m |
| jpcrp040300-q1r_E26096-000Drug Discovery And Developmentreportable segment | segment profit | 2022-01-01 → 2022-03-31 | −¥446m |
| jpcrp040300-q1r_E26096-000Drug Discovery Supportreportable segment | revenue | 2022-01-01 → 2022-03-31 | ¥129m |
| jpcrp040300-q1r_E26096-000Drug Discovery Supportreportable segment | revenue external | 2022-01-01 → 2022-03-31 | ¥129m |
| jpcrp040300-q1r_E26096-000Drug Discovery Supportreportable segment | segment profit | 2022-01-01 → 2022-03-31 | ¥71m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-01-01 → 2022-03-31 | ¥129m |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-01-01 → 2022-03-31 | ¥129m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-01-01 → 2022-03-31 | −¥375m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 321
| Item | Context | Value | Unit |
|---|---|---|---|
| Information about officers (text) | FilingDateInstant | Text · Plus | |
| Regulations in accordance with which financial statements have been prepared financial information | CurrentYTDDuration | Text · Plus | |
| Note on independent audit financial information | CurrentYTDDuration | Text · Plus | |
| Description of fact that consolidated financial statements have not been prepared financial information | CurrentYTDDuration | Original text (Japanese)当社は子会社がありませんので、四半期連結財務諸表を作成しておりません。 | |
| Quarterly balance sheet (text) | CurrentYTDDuration | Text · Plus | |
| Year to quarter end statement of income (text) | CurrentYTDDuration | Text · Plus | |
| Description of fact that quarterly statement of cash flows has not been prepared (text) | CurrentYTDDuration_NonConsolidatedMember | Text · Plus | |
| Notes when there is significant changes in amounts of equity (text) | Prior1YTDDuration_NonConsolidatedMember | Text · Plus | |
| Notes when there is significant changes in amounts of equity (text) | CurrentYTDDuration_NonConsolidatedMember | Text · Plus | |
| Notes financial instruments quarterly financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes securities quarterly financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes segment information etc quarterly financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | Prior1YTDDuration_NonConsolidatedMember | Text · Plus | |
| Information about impairment loss of non current assets or goodwill etc for each reportable segment (text) | Prior1YTDDuration_NonConsolidatedMember | Text · Plus | |
| Footnotes regarding segment information table (text) | CurrentYTDDuration_NonConsolidatedMember | Text · Plus | |
| Information about impairment loss of non current assets or goodwill etc for each reportable segment (text) | CurrentYTDDuration_NonConsolidatedMember | Text · Plus | |
| Notes revenue recognition quarterly financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes per share information quarterly financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes significant events after reporting period quarterly financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Other information financial statements etc (text) | CurrentYTDDuration | Text · Plus | |
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 10 of 10 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |